Chronic Hepatitis D Infection Clinical Trial
Official title:
An Open-label, Dose-ranging, Proof-of-Concept Study to Evaluate the Safety and Efficacy of Lonafarnib With Ritonavir-Boosting +/- Peginterferon Alfa-2a in Patients Chronically Infected With Delta Hepatitis (HDV) (LOWR-2)
An Open-label, Dose-ranging Study to Evaluate the Safety and Efficacy of Lonafarnib with Ritonavir Boosting +/- Peginterferon alfa-2a in Patients Chronically Infected with Delta Hepatitis (HDV) (LOWR-2).
Chronic delta hepatitis is a serious form of chronic liver disease caused by infection with the hepatitis D virus (HDV), a small RNA virus that requires farnesylation of its major structural protein (HDV antigen) for replication. Up to sixty subjects with chronic delta hepatitis will be randomized to receive one of ten different doses of lonafarnib. Dosing will occur over 12-48 weeks, and during that time, evidence of antiviral response will be assessed by frequent measurements of HDV-RNA. The primary therapeutic endpoint will be an improvement in quantitative serum HDV RNA levels after treatment with lonafarnib therapy. The primary safety endpoint will be the ability to tolerate the drug at the prescribed dose for the treatment duration. Several secondary endpoints will be measured, including side effects, ALT levels, and symptoms. Therapy will be stopped for intolerance to lonafarnib. This study is designed as a Phase 2a study assessing the safety, tolerance and antiviral activity of nine dosing combinations of lonafarnib with ritonavir boosting with and without peginterferon alfa-2a (PEG IFN-a). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05827146 -
Study of Hepalatide in Chronic Hepatitis D(CHD) Patients
|
Phase 2 | |
| Completed |
NCT02430181 -
Lonafarnib With and Without Ritonavir in HDV (LOWR-1)
|
Phase 2 | |
| Recruiting |
NCT05760300 -
A Multiple-Dose Study of Bulevirtide in Participants With Normal and Impaired Renal Function
|
Phase 1 | |
| Recruiting |
NCT05765344 -
Study of Bulevirtide in Participants Who Have Normal or Impaired Liver Function
|
Phase 1 | |
| Recruiting |
NCT06248580 -
Find HDV and Determine Its Status in Turkey
|
||
| Recruiting |
NCT05718700 -
Study of Bulevirtide in Participants With Chronic Hepatitis D Infection
|
||
| Completed |
NCT02637999 -
Myrcludex B Plus Pegylated Interferon-alpha-2a in Patients With HBeAg Negative HBV/HDV Co-infection
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04638439 -
The Safety and Efficacy of Sequential Treatment of Ropeginterferon Alfa-2b (P1101) and Anti-PD1 in Interferon-Naive Adults With Chronic Hepatitis B or D Infection
|
Phase 1 |